Health care stocks were mixed premarket Monday with the iShares Biotechnology ETF (IBB) 0.2% higher and the Health Care Select Sector SPDR Fund (XLV) down 0.2% recently.
Twist Bioscience (TWST) shares advanced by over 13% after the company reported a narrowed fiscal Q4 loss as revenue increased during the period.
Shares of Regenxbio (RGNX) rose by over 22% after the company reported new, positive data from the phase I/II portion of a study evaluating RGX-202 gene therapy for Duchenne muscular dystrophy.
Cybin (CYBN) shares were almost 13% higher after the company said data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers "sustained relief" through one year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。